BioLineRx Ltd.

For Immediate Release

BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update

- Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient

cohort expected to commence dosing in September -

- Announced new data showing GLIX1 achieved potent antitumor activity in TMZ-resistant

patient-derived xenograft (PDX) GBMin vivomodel -

- Announced additional data demonstrating strong synergistic effect between GLIX1 and PARP

inhibitor in patient-derived HR-proficient ovarian cancer xenograft model -

- Management to host conference call today, August 31, at 8:30 am EDT -

TEL AVIV, Israel, August 31, 2026 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended June 30, 2026, and provided a corporate update.

“During the second quarter and subsequent period, we advanced GLIX1 across multiple fronts,” stated Philip Serlin, Chief Executive Officer of BioLineRx. “Our Phase 1/2a study in glioblastoma is advancing as planned, with the second cohort in the Phase 1 part now being dosed, and the third cohort expected to commence dosing in September. To date, a little more than four months into the study, we have been very pleased with the drug’s safety and tolerability.

“Also, during the quarter, we were excited to demonstrate the potential of GLIX1 to address unmet needs for GBM as well as ovarian cancer in a number of pre-clinical models. In this regard, we announced new data in a temozolomide-resistant patient-derived xenograft (PDX) GBMin-vivo model, in which GLIX1 demonstrated a robust anti-tumor effect while TMZ showed no effect. These results further support GLIX1’s potential to treat a broad range of patients with GBM. We also generated data showing strong synergy between GLIX1 and PARP inhibitors in an HR-proficient patient-derived ovarian cancerin-vivo model, and based upon these excellent findings, we are planning to add an ovarian cancer arm to the Phase 2a expansion phase of the trial. Together, these developments keep GLIX1 on track in glioblastoma while extending its reach into additional tumor types where new treatment options are desperately needed.”